Association between non-coding circular RNAs and papillary thyroid carcinoma (Review)

Soghli,Negin; Yousefi,Tooba; Qujeq,Durdi

doi:10.3892/wasj.2020.51

Association between non-coding circular RNAs and papillary thyroid carcinoma (Review)

Authors:
- Negin Soghli
- Tooba Yousefi
- Durdi Qujeq
View Affiliations

Affiliations: Dental Materials Research Center, Institute of Health, Babol University of Medical Sciences, Babol 47176-47745, Iran, Department of Clinical Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol 47176-47745, Iran
Published online on: May 19, 2020 https://doi.org/10.3892/wasj.2020.51
Article Number: 10
Copyright: © Soghli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Papillary thyroid carcinoma (PTC) accounts for >80% of thyroid cancer cases with an increasing incidence worldwide. Despite improved diagnostic strategies and treatments, certain aggressive characteristics of PTC render the identification of alternative therapeutic approaches necessary. Circular RNAs (circRNAs) are a novel class of long non-coding RNAs (lncRNAs) containing a closed-loop structure with a covalent linkage of 3'-5' ends. Thus, they are more stable and resistant to RNA exonucleases. A significant number of recent studies on circRNAs have illustrated the dysregulated expression of these biomarkers in various types of tumors. However, the function of these non-coding RNAs and downstream mechanisms in PTC have not yet been entirely identified. In the present review article, the authors aim to discuss and summarize the functions and roles of circRNAs, including their expression profiles, potential targets and regulatory mechanisms previously recognized in PTC.

View Figures

View References

1	Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159:676–690. 2014.PubMed/NCBI View Article : Google Scholar
2	La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer mortality and incidence: A global overview. Int J Cancer. 136:2187–2195. 2015.PubMed/NCBI View Article : Google Scholar
3	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017.PubMed/NCBI View Article : Google Scholar
4	Xing M: BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev. 28:742–762. 2007.PubMed/NCBI View Article : Google Scholar
5	Sheu SY, Grabellus F, Schwertheim S, Worm K, Broecker-Preuss M and Schmid KW: Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer. 102:376–382. 2010.PubMed/NCBI View Article : Google Scholar
6	Xu B, Shao Q, Xie K, Zhang Y, Dong T, Xia Y and Tang W: The long non-coding RNA ENST00000537266 and ENST00000426615 influence papillary thyroid cancer cell proliferation and motility. Cell Physiol Biochem. 38:368–378. 2016.PubMed/NCBI View Article : Google Scholar
7	Saporito D, Brock P, Hampel H, Sipos J, Fernandez S, Liyanarachchi S, de la Chapelle A and Nagy R: Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer. 17:431–434. 2018.PubMed/NCBI View Article : Google Scholar
8	Clarke CA, Reynolds P, Oakley-Girvan I, Lee E, Lu Y, Yang J, Moy LM, Bernstein L and Horn-Ross PL: Indicators of microbial-rich environments and the development of papillary thyroid cancer in the California teachers study. Cancer Epidemiol. 39:548–553. 2015.PubMed/NCBI View Article : Google Scholar
9	Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, et al: Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab. 100:1316–1324. 2015.PubMed/NCBI View Article : Google Scholar
10	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016.PubMed/NCBI View Article : Google Scholar
11	Yin Y, Hong S, Yu S, Huang Y, Chen S, Liu Y, Zhang Q, Li Y and Xiao H: miR-195 inhibits tumor growth and metastasis in papillary thyroid carcinoma cell lines by targeting CCND1 and FGF2. Int J Endocrinol. 2017(6180425)2017.PubMed/NCBI View Article : Google Scholar
12	Ren H, Liu Z, Liu S, Zhou X, Wang H, Xu J, Wang D and Yuan G: Profile and clinical implication of circular RNAs in human papillary thyroid carcinoma. PeerJ. 6(e5363)2018.PubMed/NCBI View Article : Google Scholar
13	Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D and Ladenson PW: Detection of BRAF mutation on fine needle aspiration biopsy specimens: A new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 89:2867–2872. 2004.PubMed/NCBI View Article : Google Scholar
14	Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
15	Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ and Choi JR: Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 253:854–860. 2009.PubMed/NCBI View Article : Google Scholar
16	Haugen BR: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed? Cancer. 123:372–381. 2017.PubMed/NCBI View Article : Google Scholar
17	Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E: MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 118:3426–3432. 2012.PubMed/NCBI View Article : Google Scholar
18	Chen LL and Yang L: Regulation of circRNA biogenesis. RNA Biol. 12:381–388. 2015.PubMed/NCBI View Article : Google Scholar
19	Kos A, Dijkema R, Arnberg AC, van der Meide PH and Schellekens H: The hepatitis delta (delta) virus possesses a circular RNA. Nature. 323:558–560. 1986.PubMed/NCBI View Article : Google Scholar
20	Conn VM, Hugouvieux V, Nayak A, Conos SA, Capovilla G, Cildir G, Jourdain A, Tergaonkar V, Schmid M, Zubieta C and Conn SJ: A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation. Nat Plants. 3(17053)2017.PubMed/NCBI View Article : Google Scholar
21	Chen Y, Li C, Tan C and Liu X: Circular RNAs: A new frontier in the study of human diseases. J Med Genet. 53:359–365. 2016.PubMed/NCBI View Article : Google Scholar
22	Qian L, Yu S, Chen Z, Meng Z, Huang S and Wang P: The emerging role of circRNAs and their clinical significance in human cancers. Biochim Biophys Acta Rev Cancer. 1870:247–260. 2018.PubMed/NCBI View Article : Google Scholar
23	Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. Nature. 495:384–388. 2013.PubMed/NCBI View Article : Google Scholar
24	Li Y, Hu J, Li L, Cai S, Zhang H, Zhu X, Guan G and Dong X: Upregulated circular RNA circ_0016760 indicates unfavorable prognosis in NSCLC and promotes cell progression through miR-1287/GAGE1 axis. Biochem Biophys Res Commun. 503:2089–2094. 2018.PubMed/NCBI View Article : Google Scholar
25	Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al: Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 495:333–338. 2013.
26	Soghli N, Qujeq D, Yousefi T and Soghli N: The regulatory functions of circular RNAs in osteosarcoma. Genomics. S0888-7543:31052–31053. 2020.PubMed/NCBI View Article : Google Scholar
27	Xu B, Yang T, Wang Z, Zhang Y, Liu S and Shen M: CircRNA CDR1as/miR-7 signals promote tumor growth of osteosarcoma with a potential therapeutic and diagnostic value. Cancer Manag Res. 10:4871–4880. 2018.PubMed/NCBI View Article : Google Scholar
28	Kai D, Yannian L, Yitian C, Dinghao G, Xin Z and Wu J: Circular RNA HIPK3 promotes gallbladder cancer cell growth by sponging microRNA-124. Biochem Biophys Res Commun. 503:863–869. 2018.PubMed/NCBI View Article : Google Scholar
29	Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12:847–865. 2013.PubMed/NCBI View Article : Google Scholar
30	Huang H, Wei L, Qin T, Yang N, Li Z and Xu Z: Circular RNA ciRS-7 triggers the migration and invasion of esophageal squamous cell carcinoma via miR-7/KLF4 and NF-κB signals. Cancer Biol Ther. 20:73–80. 2019.PubMed/NCBI View Article : Google Scholar
31	Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D and Lawrie CH: CircRNAs and cancer: Biomarkers and master regulators. Semin Cancer Biol. 58:90–99. 2019.PubMed/NCBI View Article : Google Scholar
32	Chen F, Feng Z, Zhu J, Liu P, Yang C, Huang R and Deng Z: Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway. Cancer Biol Ther. 19:1139–1152. 2018.PubMed/NCBI View Article : Google Scholar
33	Kulcheski FR, Christoff AP and Margis R: Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 238:42–51. 2016.PubMed/NCBI View Article : Google Scholar
34	Peng N, Shi L, Zhang Q, Hu Y, Wang N and Ye H: Microarray profiling of circular RNAs in human papillary thyroid carcinoma. PLoS One. 12(e0170287)2017.PubMed/NCBI View Article : Google Scholar
35	Teng H, Mao F, Liang J, Xue M, Wei W, Li X, Zhang K, Feng D, Liu B and Sun Z: Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics. 8:4345–4358. 2018.PubMed/NCBI View Article : Google Scholar
36	Griffith OL, Melck A, Jones SJ and Wiseman SM: Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol. 24:5043–5051. 2006.PubMed/NCBI View Article : Google Scholar
37	Yao Y, Chen X, Yang H, Chen W, Qian Y, Yan Z, Liao T, Yao W, Wu W, Yu T, et al: Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis. J Exp Clin Cancer Res. 38(318)2019.PubMed/NCBI View Article : Google Scholar
38	Pan Y, Xu T, Liu Y, Li W and Zhang W: Upregulated circular RNA circ_0025033 promotes papillary thyroid cancer cell proliferation and invasion via sponging miR-1231 and miR-1304. Biochem Biophys Res Commun. 510:334–338. 2019.PubMed/NCBI View Article : Google Scholar
39	Yang Y, Ding L, Li Y and Xuan C: Hsa_circ_0039411 promotes tumorigenesis and progression of papillary thyroid cancer by miR-1179/ABCA9 and miR-1205/MTA1 signaling pathways. J Cell Physiol. 235:1321–1329. 2020.PubMed/NCBI View Article : Google Scholar
40	Cai X, Zhao Z, Dong J, Lv Q, Yun B, Liu J, Shen Y, Kang J and Li J: Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression. Cell Death Dis. 10(184)2019.PubMed/NCBI View Article : Google Scholar
41	Zhang J, Zhang J, Qiu W, Zhang J, Li Y, Kong E, Lu A, Xu J and Lu X: MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma. J Neurooncol. 139:547–562. 2018.PubMed/NCBI View Article : Google Scholar
42	Wang H, Wu J, Luo W and Hu J: Low expression of miR-1231 in patients with glioma and its prognostic significance. Eur Rev Med Pharmacol Sci. 22:8399–8405. 2018.PubMed/NCBI View Article : Google Scholar
43	Li CG, Pu MF, Li CZ, Gao M, Liu MX, Yu CZ, Yan H, Peng C, Zhao Y, Li Y, et al: MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1. Acta Pharmacol Sin. 38:110–119. 2017.PubMed/NCBI View Article : Google Scholar
44	Zhou GK, Zhang GY, Yuan ZN, Pei R and Liu DM: Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 22:8772–8780. 2018.PubMed/NCBI View Article : Google Scholar
45	Cargnello M, Tcherkezian J and Roux PP: The expanding role of mTOR in cancer cell growth and proliferation. Mutagenesis. 30:169–176. 2015.PubMed/NCBI View Article : Google Scholar
46	Liu F, Zhang J, Qin L, Yang Z, Xiong J, Zhang Y, Li R, Li S, Wang H, Yu B, et al: Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation. Aging (Albany NY). 10:3806–3820. 2018.PubMed/NCBI View Article : Google Scholar
47	Xiao W, Lou N, Ruan H, Bao L, Xiong Z, Yuan C, Tong J, Xu G, Zhou Y, Qu Y, et al: Mir-144-3p promotes cell proliferation, metastasis, sunitinib resistance in clear cell renal cell carcinoma by downregulating ARID1A. Cellular Cell Physiol Biochem. 43:2420–2433. 2017.PubMed/NCBI View Article : Google Scholar
48	Zhao Y, Xie Z, Lin J and Liu P: MiR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met. Am J Transl Res. 9:2437–2446. 2017.PubMed/NCBI
49	Bi W, Huang J, Nie C, Liu B, He G, Han J, Pang R, Ding Z, Xu J and Zhang J: CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway. J Exp Clin Cancer Res. 37(275)2018.PubMed/NCBI View Article : Google Scholar
50	Fu X, Zhu X, Qin F, Zhang Y, Lin J, Ding Y, Yang Z, Shang Y, Wang L, Zhang Q and Gao Q: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Cancer. 17(73)2018.PubMed/NCBI View Article : Google Scholar
51	Li X, Tian Y, Hu Y, Yang Z, Zhang L and Luo J: CircNUP214 sponges miR-145 to promote the expression of ZEB2 in thyroid cancer cells. Biochem Biophys Res Commun. 507:168–172. 2018.PubMed/NCBI View Article : Google Scholar
52	Liu Q, Chen J, Wang B, Zheng Y, Wan Y, Wang Y, Zhou L, Liu S, Li G and Yan Y: miR-145 modulates epithelial-mesenchymal transition and invasion by targeting ZEB2 in non-small cell lung cancer cell lines. J Cell Biochem: Dec 7, 2018 (Epub ahead of print).
53	Brown CY, Dayan S, Wong SW, Kaczmarek A, Hope CM, Pederson SM, Arnet V, Goodall GJ, Russell D, Sadlon TJ and Barry SC: FOXP3 and miR-155 cooperate to control the invasive potential of human breast cancer cells by down regulating ZEB2 independently of ZEB1. Oncotarget. 9:27708–27727. 2018.PubMed/NCBI View Article : Google Scholar
54	Jin X, Wang Z, Pang W, Zhou J, Liang Y, Yang J, Yang L and Zhang Q: Upregulated hsa_circ_0004458 contributes to progression of papillary thyroid carcinoma by inhibition of miR-885-5p and activation of RAC1. Med Sci Monit. 24:5488–5500. 2018.PubMed/NCBI View Article : Google Scholar
55	Chen QY, Zheng Y, Jiao DM, Chen FY, Hu HZ, Wu YQ, Song J, Yan J, Wu LJ and Lv GY: Curcumin inhibits lung cancer cell migration and invasion through Rac1-dependent signaling pathway. J Nutr Biochem. 25:177–185. 2014.PubMed/NCBI View Article : Google Scholar
56	Becker MS, Müller PM, Bajorat J, Schroeder A, Giaisi M, Amin E, Ahmadian MR, Rocks O, Köhler R, Krammer PH and Li-Weber M: The anticancer phytochemical rocaglamide inhibits Rho GTPase activity and cancer cell migration. Oncotarget. 7:51908–51921. 2016.PubMed/NCBI View Article : Google Scholar
57	Ren S, Xin Z, Xu Y, Xu J and Wang G: Construction and analysis of circular RNA molecular regulatory networks in liver cancer. Cell Cycle. 16:2204–2211. 2017.PubMed/NCBI View Article : Google Scholar
58	Liu T, Liu S, Xu Y, Shu R, Wang F, Chen C, Zeng Y and Luo H: Circular RNA-ZFR inhibited cell proliferation and promoted apoptosis in gastric cancer by sponging miR-130a/miR-107 and modulating PTEN. Cancer Res Treat. 50:1396–1417. 2018.PubMed/NCBI View Article : Google Scholar
59	Wei H, Pan L, Tao D and Li R: Circular RNA circZFR contributes to papillary thyroid cancer cell proliferation and invasion by sponging miR-1261 and facilitating C8orf4 expression. Biochem Biophys Res Commun. 503:56–61. 2018.PubMed/NCBI View Article : Google Scholar
60	Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP and Death AK: TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res. 64:2766–2773. 2004.PubMed/NCBI View Article : Google Scholar
61	Lei J, Li W, Yang Y, Lu Q, Zhang N, Bai G, Zhong D, Su K, Liu B, Li X, et al: TC-1 overexpression promotes cell proliferation in human non-small cell lung cancer that can be inhibited by PD173074. PLoS One. 9(e100075)2014.PubMed/NCBI View Article : Google Scholar
62	Tao L, Yang L, Tian P, Guo X and Chen Y: Knockdown of circPVT1 inhibits progression of papillary thyroid carcinoma by sponging miR-126. RSC Adv. 9:13316–13324. 2019.
63	Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA and Kebebew E: Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol. 18:3443–34452. 2011.PubMed/NCBI View Article : Google Scholar
64	Wu G, Zhou W, Lin X, Sun Y, Li J, Xu H, Shi P, Gao L and Tian X: CircRASSF2 Acts as ceRNA and promotes papillary thyroid carcinoma progression through miR-1178/TLR4 signaling pathway. Mol Ther Nucleic Acids. 19:1153–1163. 2020.PubMed/NCBI View Article : Google Scholar
65	Zhang W, Zhang H and Zhao X: Circ_0005273 promotes thyroid carcinoma progression by SOX2 expression. Endocr Relat Cancer. 27:11–21. 2020.PubMed/NCBI View Article : Google Scholar
66	Li F, Ma K, Sun M and Shi S: Identification of the tumor-suppressive function of circular RNA ITCH in glioma cells through sponging miR-214 and promoting linear ITCH expression. Am J Transl Res. 10:1373–1386. 2018.PubMed/NCBI
67	Wang M, Chen B, Ru Z and Cong L: CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/β-catenin pathway. Biochem Biophys Res Commun. 504:283–288. 2018.PubMed/NCBI View Article : Google Scholar
68	Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, et al: C-Cbl mediates the degradation of tumorigenic nuclear β-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 7:71136–71150. 2016.PubMed/NCBI View Article : Google Scholar
69	Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P and Basolo F: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 92:4085–4090. 2007.PubMed/NCBI View Article : Google Scholar
70	Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A and Basolo F: BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab. 93:3943–3949. 2008.PubMed/NCBI View Article : Google Scholar
71	Lan X, Cao J, Xu J, Chen C, Zheng C, Wang J, Zhu X, Zhu X and Ge M: Decreased expression of hsa_circ_0137287 predicts aggressive clinicopathologic characteristics in papillary thyroid carcinoma. J Clin Lab Anal. 32(e22573)2018.PubMed/NCBI View Article : Google Scholar
72	Siegel RL, Miller KD and Jemal A: Cancer statistics 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
73	Lan X, Xu J, Chen C, Zheng C, Wang J, Cao J, Zhu X and Ge M: The landscape of circular RNA expression profiles in papillary thyroid carcinoma based on RNA sequencing. Cell Physiol Biochem. 47:1122–1132. 2018.PubMed/NCBI View Article : Google Scholar
74	Liu Q, Pan LZ, Hu M and Ma JY: Molecular Network-Based identification of circular RNA-Associated ceRNA network in papillary thyroid cancer. Pathol Oncol Res 2019 [Epub ahead of print].